|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBQLN4 |
Gene summary for UBQLN4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBQLN4 | Gene ID | 56893 |
| Gene name | ubiquilin 4 | |
| Gene Alias | A1U | |
| Cytomap | 1q22 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | B4DZF6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56893 | UBQLN4 | LZE2T | Human | Esophagus | ESCC | 6.94e-04 | 4.47e-01 | 0.082 |
| 56893 | UBQLN4 | LZE7T | Human | Esophagus | ESCC | 2.96e-04 | 2.82e-01 | 0.0667 |
| 56893 | UBQLN4 | LZE22T | Human | Esophagus | ESCC | 1.44e-08 | 3.44e-01 | 0.068 |
| 56893 | UBQLN4 | LZE24T | Human | Esophagus | ESCC | 1.74e-14 | 2.53e-01 | 0.0596 |
| 56893 | UBQLN4 | LZE21T | Human | Esophagus | ESCC | 3.14e-03 | 1.87e-01 | 0.0655 |
| 56893 | UBQLN4 | P2T-E | Human | Esophagus | ESCC | 1.00e-24 | 4.06e-01 | 0.1177 |
| 56893 | UBQLN4 | P4T-E | Human | Esophagus | ESCC | 8.20e-14 | 3.44e-01 | 0.1323 |
| 56893 | UBQLN4 | P5T-E | Human | Esophagus | ESCC | 1.52e-12 | 2.66e-01 | 0.1327 |
| 56893 | UBQLN4 | P8T-E | Human | Esophagus | ESCC | 1.85e-18 | 3.48e-01 | 0.0889 |
| 56893 | UBQLN4 | P9T-E | Human | Esophagus | ESCC | 2.54e-16 | 3.54e-01 | 0.1131 |
| 56893 | UBQLN4 | P10T-E | Human | Esophagus | ESCC | 1.53e-19 | 2.83e-01 | 0.116 |
| 56893 | UBQLN4 | P11T-E | Human | Esophagus | ESCC | 1.28e-08 | 3.44e-01 | 0.1426 |
| 56893 | UBQLN4 | P12T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.30e-01 | 0.1122 |
| 56893 | UBQLN4 | P15T-E | Human | Esophagus | ESCC | 1.28e-16 | 4.01e-01 | 0.1149 |
| 56893 | UBQLN4 | P16T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.18e-01 | 0.1153 |
| 56893 | UBQLN4 | P17T-E | Human | Esophagus | ESCC | 1.45e-05 | 3.25e-01 | 0.1278 |
| 56893 | UBQLN4 | P19T-E | Human | Esophagus | ESCC | 8.06e-09 | 6.78e-01 | 0.1662 |
| 56893 | UBQLN4 | P20T-E | Human | Esophagus | ESCC | 5.39e-15 | 2.19e-01 | 0.1124 |
| 56893 | UBQLN4 | P21T-E | Human | Esophagus | ESCC | 8.08e-19 | 3.50e-01 | 0.1617 |
| 56893 | UBQLN4 | P22T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.15e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:1903362111 | Esophagus | ESCC | regulation of cellular protein catabolic process | 188/8552 | 255/18723 | 5.12e-20 | 6.62e-18 | 188 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:1903050111 | Esophagus | ESCC | regulation of proteolysis involved in cellular protein catabolic process | 163/8552 | 221/18723 | 1.44e-17 | 1.27e-15 | 163 |
| GO:0061136111 | Esophagus | ESCC | regulation of proteasomal protein catabolic process | 142/8552 | 187/18723 | 2.40e-17 | 2.00e-15 | 142 |
| GO:0032434111 | Esophagus | ESCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 107/8552 | 134/18723 | 4.06e-16 | 2.93e-14 | 107 |
| GO:2000058111 | Esophagus | ESCC | regulation of ubiquitin-dependent protein catabolic process | 125/8552 | 164/18723 | 1.17e-15 | 7.76e-14 | 125 |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:001624114 | Esophagus | ESCC | regulation of macroautophagy | 102/8552 | 141/18723 | 1.09e-10 | 3.27e-09 | 102 |
| GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| GO:0031330111 | Esophagus | ESCC | negative regulation of cellular catabolic process | 166/8552 | 262/18723 | 5.17e-09 | 1.08e-07 | 166 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:00973523 | Esophagus | ESCC | autophagosome maturation | 31/8552 | 40/18723 | 4.04e-05 | 3.26e-04 | 31 |
| GO:00062826 | Esophagus | ESCC | regulation of DNA repair | 82/8552 | 130/18723 | 4.65e-05 | 3.66e-04 | 82 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
| hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
| hsa0501429 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
| hsa04141210 | Oral cavity | LP | Protein processing in endoplasmic reticulum | 113/2418 | 174/8465 | 8.74e-24 | 5.82e-22 | 3.76e-22 | 113 |
| hsa0501437 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
| hsa0414138 | Oral cavity | LP | Protein processing in endoplasmic reticulum | 113/2418 | 174/8465 | 8.74e-24 | 5.82e-22 | 3.76e-22 | 113 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBQLN4 | SNV | Missense_Mutation | c.1223N>C | p.Ser408Thr | p.S408T | Q9NRR5 | protein_coding | deleterious(0.05) | benign(0.263) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| UBQLN4 | SNV | Missense_Mutation | novel | c.1176G>T | p.Glu392Asp | p.E392D | Q9NRR5 | protein_coding | tolerated(0.18) | benign(0.109) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBQLN4 | SNV | Missense_Mutation | rs757542069 | c.211N>A | p.Gly71Arg | p.G71R | Q9NRR5 | protein_coding | deleterious(0) | possibly_damaging(0.863) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| UBQLN4 | SNV | Missense_Mutation | c.1610N>C | p.Met537Thr | p.M537T | Q9NRR5 | protein_coding | deleterious(0.02) | benign(0.416) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| UBQLN4 | SNV | Missense_Mutation | c.999G>C | p.Trp333Cys | p.W333C | Q9NRR5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBQLN4 | SNV | Missense_Mutation | c.817N>C | p.Glu273Gln | p.E273Q | Q9NRR5 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBQLN4 | SNV | Missense_Mutation | c.637N>A | p.Asp213Asn | p.D213N | Q9NRR5 | protein_coding | tolerated(0.06) | probably_damaging(0.98) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| UBQLN4 | SNV | Missense_Mutation | novel | c.1269N>A | p.Met423Ile | p.M423I | Q9NRR5 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UBQLN4 | SNV | Missense_Mutation | rs374330338 | c.848N>A | p.Arg283His | p.R283H | Q9NRR5 | protein_coding | deleterious(0.03) | probably_damaging(0.962) | TCGA-A6-2675-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBQLN4 | SNV | Missense_Mutation | c.1088N>T | p.Ser363Leu | p.S363L | Q9NRR5 | protein_coding | tolerated(0.06) | possibly_damaging(0.561) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |